Chemclin Diagnostics Co., Ltd. (SHA:688468)

Market Cap	2.84B
Revenue (ttm)	406.20M
Net Income (ttm)	103.23M
Shares Out	394.59M
EPS (ttm)	0.26
PE Ratio	27.34
Forward PE	n/a
Dividend	0.13 (1.74%)
Ex-Dividend Date	Jun 14, 2024

Volume	3,645,285
Average Volume	3,830,320
Open	7.28
Previous Close	7.28
Day's Range	7.19 - 7.34
52-Week Range	5.28 - 9.11
Beta	-0.03
RSI	50.76
Earnings Date	Aug 29, 2025

About Chemclin Diagnostics

Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such as hepatitis B, hepatitis C, AIDS, syphilis, hepatitis A, hepatitis E, etc.; and detection of tumor markers, thyroid hormones, reproductive endocrine ho...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2007
• Employees: 629
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688468

Financial Performance

In 2024, Chemclin Diagnostics's revenue was 436.29 million, a decrease of -2.03% compared to the previous year's 445.34 million. Earnings were 127.07 million, a decrease of -13.77%.